REVA appoints new managing director
REVA Medical (ASX:RVA) has named Michel Vanbrabant as its new managing director as it prepares for the European market launch of coronary scaffold ReZolve2.
Vanbrabant has significant experience commercialising medical devices, having spent more than 10 years at cardiovascular medical product company Guidant Corporation (now Abbott Labs).
He has also held senior positions at St Jude Medical and early-stage company PneumRx. At the latter, he oversaw the commercial launch of the company’s emphysema implants.
REVA chairman and CEO Bob Stockman said Vanbrabant will help the company navigate the European launch of ReZolve 2, which is expected by end-2014.
“As we move toward European CE Marking, Michel will work with our executive team to formulate the detailed commercial plans for our scaffold, with specific focus on sales, distribution and reimbursement,” he said.
ReZolve2 is the improved version of REVA’s drug-eluting bioresorbable coronary scaffold ReZolve.
REVA Medical shares were trading 1.85% lower at $0.53 as of around 2.30 pm on Tuesday.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
